Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT)

Why this trial sits in Marine omega-3

Icosapent ethyl is a highly purified EPA ethyl ester—a long-chain marine omega-3 product class—tested at 4 g/day total EPA equivalent dosing, not a typical low-dose mixed EPA/DHA retail capsule.

Population & design (headline)

• N ≈ 8,179; median follow-up 4.9 years
• Inclusion: statin-treated patients with fasting TG 135–499 mg/dL and LDL-C 41–100 mg/dL, with ASCVD or diabetes + other risk factors
• Intervention: 2 g icosapent ethyl twice daily vs placebo
• Primary endpoint: composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina

Principal efficacy signals (published primary analysis)

• Primary composite: HR 0.75 (95% CI 0.68–0.83; p<0.001); 17.2% vs 22.0% event rates
• Key secondary (CV death + nonfatal MI + nonfatal stroke): HR 0.74 (95% CI 0.65–0.83; p<0.001)
• Cardiovascular death: HR 0.80 (95% CI 0.66–0.98; p=0.03)

Safety / nuance for readers

• Atrial fibrillation/flutter hospitalization: 3.1% vs 2.1% (p=0.004)
• Serious bleeding: 2.7% vs 2.1% (p=0.06)
• Comparator controversy: placebo arm used mineral oil; later debates ask how much of the effect estimate reflects EPA versus comparator physiology—read guideline updates and secondary analyses, not only the primary abstract.

How to use next to Hooper Cochrane

Hooper et al. pools many long-duration LCn3 trials across mixed formulations, doses, and populations, often showing little all-cause mortality benefit. REDUCE-IT is a single high-dose prescription EPA program in a high-risk, elevated-TG-on-statin niche—evidence for icosapent labeling, not automatic proof that any fish oil matches these outcomes.